A personalized cancer vaccine could be available as soon as 2027. Here’s what we know

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising results in a late-stage clinical trial.

[Source images: Adobe Stock]

A breakthrough treatment for the deadliest form of skin cancer can cut a patient’s risk of recurrence or death nearly in half. 

The new scientific revelation is powered by an mRNA-based vaccine crafted with the technology behind both Pfizer and Moderna’s landmark COVID-19 shots. By using mRNA (messenger ribonucleic acid), the vaccine can be customized for the genetic profile of an individual patient’s skin cancer, fighting........

© Fast Company